Source comparison
The Definitive Truth About Ipamorelin Oral vs Injectable
Here's the honest answer: oral ipamorelin is not a legitimate research tool. It's a product created to meet consumer demand for needle-free peptides, not to meet scientific standards for reproducible pharmacology. Zero peer-reviewed studies have demonstrated g
This comparison does not assign a generated winner or score.
- Here's the honest answer: oral ipamorelin is not a legitimate research tool. It's a product created to meet consumer demand for needle-free peptides, not to meet scientific standards for reproducible pharmacology. Zero peer-reviewed studies have demonstrated growth hormone elevation from orally administered ipamorelin in any species. Human, rodent, or primate. The absence of evidence isn't because researchers haven't tried; it's because the mechanism of oral peptide degradation is well-characterised and insurmountable with current technology. Gastric pH denatures protein structure. Pepsin cleaves peptide bonds. Intestinal proteases fragment anything that survives the stomach. This isn't a formulation problem that better excipients could solve. It's a biochemical inevitability.
- Injectable ipamorelin, by contrast, has been used in hundreds of published studies since its synthesis in 1998, with consistent pharmacokinetic profiles across species and administration contexts. The 2004 study by Raun et al. in the European Journal of Endocrinology established the EC50 for GH release at 1.3 nM and demonstrated selectivity for GHS-R1a without prolactin or cortisol elevation. Data generated using intravenous and subcutaneous administration exclusively. When Real Peptides sources Ipamorelin, we're supplying the same molecular format used in that foundational research, manufactured to the same purity standards (≥98% by HPLC), and delivered in the same lyophilised form that preserves activity through storage and reconstitution. We don't offer oral ipamorelin because we don't sell products that don't work.
- The comparison isn't close. Injectable bioavailability exceeds oral by 80- to 100-fold. Injectable stability exceeds oral by 18–24 months. Injectable pharmacokinetics are reproducible and dose-dependent; oral pharmacokinetics are undetectable. If your research question involves growth hormone secretion, metabolic endpoints, or any outcome downstream of GHS-R1a activation, subcutaneous injection is the only format worth considering. The peptide must reach the receptor in active form. Everything else is expensive placebo.
- Researchers serious about peptide science don't debate ipamorelin oral vs injectable. They source high-purity lyophilised peptides, reconstitute under sterile technique, and administer via subcutaneous injection using validated protocols. If your current supplier is offering oral ipamorelin as a "convenient alternative," they're offering convenience at the cost of efficacy. Real Peptides manufactures every peptide in our catalogue. Including CJC1295 Ipamorelin 5MG 5MG combination vials and standalone Ipamorelin. Through small-batch synthesis with exact amino-acid sequencing and third-party purity verification. We guarantee ≥98% purity because research depends on knowing exactly what molecule you're administering. Oral formats can't make that guarantee, because the molecule that reaches systemic circulation isn't the molecule on the label. It's fragments, metabolites, and trace amounts of intact peptide insufficient for receptor binding.
- When protocol design matters, delivery format matters. Injectable ipamorelin preserves molecular integrity from synthesis through receptor activation. Oral ipamorelin doesn't.